X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs FRESENIUS KABI ONCO. - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS FRESENIUS KABI ONCO. IPCA LABS/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 27.6 22.1 124.9% View Chart
P/BV x 3.3 3.1 105.3% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    IPCA LABS
Mar-18
FRESENIUS KABI ONCO.
Mar-13
IPCA LABS/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs695176 395.1%   
Low Rs40079 509.6%   
Sales per share (Unadj.) Rs260.237.7 690.4%  
Earnings per share (Unadj.) Rs19.05.1 372.5%  
Cash flow per share (Unadj.) Rs33.16.7 491.7%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs213.042.5 500.7%  
Shares outstanding (eoy) m126.20158.23 79.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.13.4 62.3%   
Avg P/E ratio x28.925.0 115.6%  
P/CF ratio (eoy) x16.618.9 87.5%  
Price / Book Value ratio x2.63.0 86.0%  
Dividend payout %5.30-   
Avg Mkt Cap Rs m69,12020,135 343.3%   
No. of employees `00013.31.2 1,150.5%   
Total wages/salary Rs m7,359703 1,046.5%   
Avg. sales/employee Rs Th2,477.45,176.2 47.9%   
Avg. wages/employee Rs Th555.2610.4 91.0%   
Avg. net profit/employee Rs Th180.6699.6 25.8%   
INCOME DATA
Net Sales Rs m32,8365,963 550.7%  
Other income Rs m41818 2,322.2%   
Total revenues Rs m33,2545,981 556.0%   
Gross profit Rs m4,5051,430 315.0%  
Depreciation Rs m1,777258 689.1%   
Interest Rs m240-26 -923.8%   
Profit before tax Rs m2,9051,216 238.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m511342 149.4%   
Profit after tax Rs m2,394806 297.1%  
Gross profit margin %13.724.0 57.2%  
Effective tax rate %17.628.1 62.5%   
Net profit margin %7.313.5 54.0%  
BALANCE SHEET DATA
Current assets Rs m19,4555,102 381.3%   
Current liabilities Rs m10,0762,385 422.4%   
Net working cap to sales %28.645.6 62.7%  
Current ratio x1.92.1 90.3%  
Inventory Days Days98150 65.2%  
Debtors Days Days67113 59.1%  
Net fixed assets Rs m20,2605,148 393.5%   
Share capital Rs m252158 159.5%   
"Free" reserves Rs m26,6336,556 406.3%   
Net worth Rs m26,8866,732 399.4%   
Long term debt Rs m2,340952 245.8%   
Total assets Rs m41,17310,388 396.4%  
Interest coverage x13.1-45.8 -28.6%   
Debt to equity ratio x0.10.1 61.5%  
Sales to assets ratio x0.80.6 138.9%   
Return on assets %6.47.5 85.2%  
Return on equity %8.912.0 74.4%  
Return on capital %10.814.6 73.7%  
Exports to sales %47.674.5 64.0%   
Imports to sales %14.924.8 60.0%   
Exports (fob) Rs m15,6424,441 352.3%   
Imports (cif) Rs m4,8841,477 330.6%   
Fx inflow Rs m15,6425,298 295.3%   
Fx outflow Rs m4,8841,772 275.6%   
Net fx Rs m10,7593,525 305.2%   
CASH FLOW
From Operations Rs m3,4111,274 267.7%  
From Investments Rs m-1,354-1,204 112.4%  
From Financial Activity Rs m-1,304-196 665.0%  
Net Cashflow Rs m753-126 -596.4%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 11.4 0.3 3,800.0%  
FIIs % 25.3 9.6 263.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 9.1 191.2%  
Shareholders   36,892 42,599 86.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  NOVARTIS  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Weak; FMCG Stocks Drag(12:30 pm)

Stock markets in India are trading in negative territory weighed by fast-moving consumer goods (FMCG) stocks.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 26, 2018 02:03 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS